Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.83 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.83 |
| ▸ | MAPT | P10636 | 2/20 | 0.83 |
| ▸ | LMNA | P02545 | 1/20 | 0.83 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.74 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.74 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.74 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.74 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.74 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.74 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.74 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.74 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.74 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.74 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.74 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | CASP3 | P42574 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.60 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL96371 | 1.00 | TDP1 (0.83) | TDP1L3MBTL1MAPTLMNAHDAC1 | |
| SCHEMBL8214391 | 1.00 | TDP1 (0.83) | TDP1L3MBTL1MAPTLMNAHDAC1 | |
| SCHEMBL95198 | 0.98 | TDP1 (0.79) | TDP1L3MBTL1MAPTLMNAHDAC1 | |
| SCHEMBL94886 | 0.91 | TDP1 (0.75) | TDP1L3MBTL1MAPTLMNAHDAC1 | |
| SCHEMBL27516050 | 0.91 | TDP1 (1.00) | TDP1L3MBTL1MAPTLMNAHDAC1 | |
| SCHEMBL9057671 | 0.91 | TDP1 (1.00) | TDP1L3MBTL1MAPTLMNAHDAC1 | |
| SCHEMBL8519287 | 0.91 | TDP1 (1.00) | TDP1L3MBTL1MAPTLMNAHDAC1 | |
| Acetaldehyde SCHEMBL27387803 | 0.91 | L3MBTL1 (0.69) | TDP1L3MBTL1MAPTLMNAHDAC1 | |
| SCHEMBL7068671 | 0.89 | TDP1 (0.95) | TDP1L3MBTL1MAPTLMNAHDAC1 | |
| SCHEMBL4443771 | 0.89 | HDAC8 (0.69) | TDP1L3MBTL1MAPTLMNAHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102741200-B | Dehydrogenation and method | 埃克森美孚化学专利公司 | 2016-08-24 | — | — | CN | disclosed |
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| CN-102741200-A | Dehydrogenation catalyst and process | EXXONMOBIL CHEM PATENTS INC | 2012-10-17 | — | — | CN | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2043644-A1 | NF- B INHIBITOR | Otsuka Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008010601-A1 | NF- ϰB INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | WO | disclosed |
| EP-1797082-A1 | CARBOSTYRIL COMPOUND | Otsuka Pharmaceutical Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| EP-1221440-B1 | Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators | OTSUKA PHARMA CO LTD (JP) | 2007-04-25 | — | — | EP | disclosed |
| WO-2006035954-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | disclosed |
| US-6642223-B2 | A benzoazepin or benzodiazepin derivatives, shows excellent anti-vasopressin activity, vasopressin agonistic activity and oxytocin antagonistic activity, and are useful as antagonist | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2003-11-04 | — | — | US | disclosed |
| EP-1221440-A1 | Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators | Otsuka Pharmaceutical Company, Limited (JP) | 2002-07-10 | — | — | EP | disclosed |
| US-20020049194-A1 | Benzoheterocyclic derivatives | OGAWA HIDENORI (JP) | 2002-04-25 | — | — | US | disclosed |
| US-6335327-B1 | Benzoheterocyclic derivatives | OTSUKA PHARMACEUTICALS CO., LTD. (JP) | 2002-01-01 | — | — | US | disclosed |
| US-6096735-A | Benzoheterocyclic derivatives | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2000-08-01 | — | — | US | disclosed |
| EP-0765314-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995034540-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | TDP1 3588/4885L3MBTL1 1099/4885MAPT 4112/4885 |
| US-20020049194-A1 | Benzoheterocyclic derivatives | AVPR2, AVPR1A, AVPR1B | TDP1 3264/4885L3MBTL1 3872/4885MAPT 3643/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | TDP1 4079/4885L3MBTL1 262/4885MAPT 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.